| dc.creator |
Deger, Serpil Muge |
|
| dc.creator |
Gumusay, Ozge |
|
| dc.creator |
ÖZET, AHMET |
|
| dc.creator |
Benekli, Mustafa |
|
| dc.creator |
Coskun, Ugur |
|
| dc.creator |
Buyukberber, Suleyman |
|
| dc.creator |
Cetin, Bulent |
|
| dc.creator |
Afsar, Barış |
|
| dc.creator |
Gonul, Ipek Isik |
|
| dc.date |
2014-06-01T00:00:00Z |
|
| dc.date.accessioned |
2021-12-03T11:15:31Z |
|
| dc.date.available |
2021-12-03T11:15:31Z |
|
| dc.identifier |
156672a4-1d4b-4f63-a21a-3d9999f21ad9 |
|
| dc.identifier |
10.1007/s11255-013-0613-x |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/156672a4-1d4b-4f63-a21a-3d9999f21ad9/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/90096 |
|
| dc.description |
There are no robust data on hemoglobin (Hb), lactate dehydrogenase (LDH), and calcium variability for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. We aim to evaluate prognostic implications of Hb, LDH, and calcium variability and establish a novel risk stratification model in RCC patients receiving targeted therapies. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma |
|
| dc.type |
info:eu-repo/semantics/article |
|